The CEO's discussion of the melanoma vaccine trial data on a major financial news network is likely to be viewed positively by investors, as it suggests progress in Moderna's product development. Positive trial results can lead to increased investor confidence in the company's pipeline and its ability to generate future revenue, which can drive the stock price up in the short term.